Literature DB >> 10582869

Interaction between fluconazole and amphotericin B in mice with systemic infection due to fluconazole-susceptible or -resistant strains of Candida albicans.

A Louie1, P Banerjee, G L Drusano, M Shayegani, M H Miller.   

Abstract

The interaction between fluconazole (Flu) and amphotericin B (AmB) was evaluated in a murine model of systemic candidiasis for one Flu-susceptible strain (MIC, 0.5 microg/ml), two strains with intermediate Flu resistance (Flu mid-resistant strains) (MIC, 64 and 128 microg/ml), and one highly Flu-resistant strain (MIC, 512 microg/ml) of Candida albicans. Differences in fungal densities in kidneys of infected mice after 24 h of therapy and in survival rates at 62 days of mice treated with an antifungal drug or a combination of antifungal drugs for 4 days were compared. For the Flu-susceptible and Flu mid-resistant strains, the combination of Flu and AmB was antagonistic, as shown by both quantitative culture results and survival. The interaction was additive for the highly Flu-resistant strain. These results suggest that the combination of Flu and AmB should be used with caution in infections due to fungi that are usually susceptible to both antifungal agents and as empirical antifungal drug therapy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10582869      PMCID: PMC89574          DOI: 10.1128/AAC.43.12.2841

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  21 in total

Review 1.  Amphotericin B: current understanding of mechanisms of action.

Authors:  J Brajtburg; W G Powderly; G S Kobayashi; G Medoff
Journal:  Antimicrob Agents Chemother       Date:  1990-02       Impact factor: 5.191

Review 2.  Fluconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses.

Authors:  S M Grant; S P Clissold
Journal:  Drugs       Date:  1990-06       Impact factor: 9.546

3.  Hospital-acquired candidemia. The attributable mortality and excess length of stay.

Authors:  S B Wey; M Mori; M A Pfaller; R F Woolson; R P Wenzel
Journal:  Arch Intern Med       Date:  1988-12

4.  Efficacies of high-dose fluconazole plus amphotericin B and high-dose fluconazole plus 5-fluorocytosine versus amphotericin B, fluconazole, and 5-fluorocytosine monotherapies in treatment of experimental endocarditis, endophthalmitis, and pyelonephritis due to Candida albicans.

Authors:  A Louie; W Liu; D A Miller; A C Sucke; Q F Liu; G L Drusano; M Mayers; M H Miller
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

5.  Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System.

Authors:  C Beck-Sagué; W R Jarvis
Journal:  J Infect Dis       Date:  1993-05       Impact factor: 5.226

6.  Pharmacokinetic studies of fluconazole in rabbits characterizing doses which achieve peak levels in serum and area under the concentration-time curve values which mimic those of high-dose fluconazole in humans.

Authors:  A Louie; Q F Liu; G L Drusano; W Liu; M Mayers; E Anaissie; M H Miller
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

Review 7.  Oral azole drugs as systemic antifungal therapy.

Authors:  J A Como; W E Dismukes
Journal:  N Engl J Med       Date:  1994-01-27       Impact factor: 91.245

8.  Interactions in vitro between polyenes and imidazoles against yeasts.

Authors:  M A Petrou; T R Rogers
Journal:  J Antimicrob Chemother       Date:  1991-04       Impact factor: 5.790

9.  Sensitive high-pressure liquid chromatographic assay for amphotericin B which incorporates an internal standard.

Authors:  G G Granich; G S Kobayashi; D J Krogstad
Journal:  Antimicrob Agents Chemother       Date:  1986-04       Impact factor: 5.191

10.  Sensitive bioassay for ketoconazole in serum and cerebrospinal fluid.

Authors:  J H Jorgensen; G A Alexander; J R Graybill; D J Drutz
Journal:  Antimicrob Agents Chemother       Date:  1981-07       Impact factor: 5.191

View more
  20 in total

Review 1.  In vivo pharmacodynamics of antifungal drugs in treatment of candidiasis.

Authors:  David Andes
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

Review 2.  Combination antifungal therapy.

Authors:  Melissa D Johnson; Conan MacDougall; Luis Ostrosky-Zeichner; John R Perfect; John H Rex
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

3.  Need for early antifungal treatment confirmed in experimental disseminated Candida albicans infection.

Authors:  Donna M MacCallum; Frank C Odds
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

4.  Voriconazole-induced inhibition of the fungicidal activity of amphotericin B in Candida strains with reduced susceptibility to voriconazole: an effect not predicted by the MIC value alone.

Authors:  Anders Lignell; Elisabeth Löwdin; Otto Cars; Dominique Sanglard; Jan Sjölin
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

5.  Impact of the order of initiation of fluconazole and amphotericin B in sequential or combination therapy on killing of Candida albicans in vitro and in a rabbit model of endocarditis and pyelonephritis.

Authors:  A Louie; P Kaw; P Banerjee; W Liu; G Chen; M H Miller
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

6.  Dosage-dependent antifungal efficacy of V-echinocandin (LY303366) against experimental fluconazole-resistant oropharyngeal and esophageal candidiasis.

Authors:  V Petraitis; R Petraitiene; A H Groll; T Sein; R L Schaufele; C A Lyman; A Francesconi; J Bacher; S C Piscitelli; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

Review 7.  Combination treatment of invasive fungal infections.

Authors:  Pranab K Mukherjee; Daniel J Sheehan; Christopher A Hitchcock; Mahmoud A Ghannoum
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

8.  The in vitro and in vivo efficacy of fluconazole in combination with farnesol against Candida albicans isolates using a murine vulvovaginitis model.

Authors:  Aliz Bozó; Marianna Domán; László Majoros; Gábor Kardos; István Varga; Renátó Kovács
Journal:  J Microbiol       Date:  2016-10-29       Impact factor: 3.422

9.  In vitro activities of voriconazole in combination with three other antifungal agents against Candida glabrata.

Authors:  Francesco Barchiesi; Elisabetta Spreghini; Monia Maracci; Annette W Fothergill; Isabella Baldassarri; Michael G Rinaldi; Giorgio Scalise
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

10.  Candida parapsilosis peritonitis in patients on CAPD.

Authors:  Charoen Kaitwatcharachai
Journal:  Mycopathologia       Date:  2002       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.